| Literature DB >> 30424528 |
Xue Liu1,2,3, Peng Du4, Xiao Liu5, Sujian Cao6, Ling Qin7, Meijia He8, Xiaoxi He9,10, Wenjun Mao11,12.
Abstract
The active sulfated polysaccharide from seaweed possesses important pharmaceutical and biomedical potential. In the study, Monostroma sulfated polysaccharide (MSP) was obtained from Monostroma angicava, and the low-molecular-weight fragments of MSP (MSP-Fs: MSP-F1⁻MSP-F6) were prepared by controlled acid degradation. The molecular weights of MSP and MSP-F1⁻MSP-F6 were 335 kDa, 240 kDa, 90 kDa, 40 kDa, 24 kDa, 12 kDa, and 6.8 kDa, respectively. The polysaccharides were sulfated rhamnans that consisted of →3)-α-l-Rhap-(1→ and →2)-α-l-Rhap-(1→ units with partial sulfation at C-2 of →3)-α-l-Rhap-(1→ and C-3 of →2)-α-l-Rhap-(1→. Anticoagulant properties in vitro of MSP and MSP-F1⁻MSP-F6 were evaluated by studying the activated partial thromboplastin time, thrombin time, and prothrombin time. Anticoagulant activities in vivo of MSP and MSP-F4 were further evaluated; their fibrin(ogen)olytic activities in vivo and thrombolytic properties in vitro were also assessed by D-dimer, fibrin degradation products, plasminogen activator inhibitior-1, and clot lytic rate assays. The results showed that MSP and MSP-F1⁻MSP-F4 with molecular weights of 24⁻240 kDa had strong anticoagulant activities. A decrease in the molecular weight of MSP-Fs was accompanied by a decrease in the anticoagulant activity, and higher anticoagulant activity requires a molecular weight of over 12 kDa. MSP and MSP-F4 possessed strong anticoagulant activities in vivo, as well as high fibrin(ogen)olytic and thrombolytic activities. MSP and MSP-F4 have potential as drug or helpful food supplements for human health.Entities:
Keywords: anticoagulant activity; depolymerization; fibrin(ogen)olytic activity; low-molecular-weight fractions; sulfated polysaccharide; thrombolytic activity
Mesh:
Substances:
Year: 2018 PMID: 30424528 PMCID: PMC6266706 DOI: 10.3390/md16110445
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1High-performance gel permeation chromatography (HPGPC) chromatograms of Monostroma sulfated polysaccharide (MSP) and low-molecular-weight MSP fractions (MSP-Fs). (a) HPGPC chromatogram of MSP (A) and the standard curve of molecular weight (B); (b) HPGPC chromatograms of MSP-Fs.
Chemical compositions of MSP and MSP-F1–MSP-F6.
| Sample | Molecular Weight (kDa) | Sulfate Content (w%) | Monosaccharide Content (mol%) | |
|---|---|---|---|---|
| Rha | Xyl | |||
| MSP | 335 | 27.32 | 94.74 | 5.26 |
| MSP-F1 | 240 | 27.15 | 94.92 | 5.08 |
| MSP-F2 | 90 | 27.30 | 95.45 | 4.55 |
| MSP-F3 | 40 | 27.88 | 96.68 | 3.32 |
| MSP-F4 | 24 | 27.61 | 96.72 | 3.28 |
| MSP-F5 | 12 | 28.32 | 97.05 | 2.95 |
| MSP-F6 | 6.8 | 28.10 | 97.14 | 2.86 |
Methylation analyses of MSP and MSP-Ds.
| Methylated Alditol Acetate | Molar Ratio (mol%) | Linkage Pattern | |
|---|---|---|---|
| MSP | MSP-Ds | ||
| 1,3,5-tri- | 37.52 | 59.01 | →3)-Rha |
| 1,2,5-tri- | 26.33 | 29.60 | →2)-Rha |
| 1,2,3,5-tetra- | 30.89 | 6.13 | →2,3)-Rha |
| 1,4,5-Tri- | 5.26 | nd a | →4)-Xyl |
| 1,5-Di- | nd a | 5.26 | Xyl |
a Not detected.
Figure 2NMR spectra of MSP-Ds. (a) 1H NMR; (b) 13C NMR; (c) 1H–1H COSY; (d) 1H–13C HSQC; (e) 1H–13C HMBC. A: →3)-α-l-Rhap-(1→; B: →3)-α-l-Rhap-(1→; C: →2)-α-l-Rhap-(1→; D: →2)-α-l-Rhap(3SO4)-(1→. Rhap: rhamnopyranose.
1H and 13C chemical shifts for MSP-Ds.
| Rhamnose Residues a | Chemical Shifts (ppm) | |||||
|---|---|---|---|---|---|---|
| H1/C1 | H2/C2 | H3/C3 | H4/C4 | H5/C5 | H6/C6 | |
| A | 4.99/103.66 | 4.20/70.82 | 3.89/79.55 | 3.58/73.18 | 3.79/70.82 | 1.33/18.23 |
| B | 5.07/103.66 | 4.20/70.82 | 3.93/79.55 | 3.57/73.18 | 3.79/70.82 | 1.33/18.23 |
| C | 5.22/102.45 | 4.11/79.12 | 3.98/71.43 | 3.60/70.79 | 3.79/70.82 | 1.33/18.23 |
| D | 5.37/102.45 | 4.25/78.85 | 4.51/78.85 | 3.59/70.79 | 3.79/70.82 | 1.33/18.23 |
a A: →3)-α-l-Rhap-(1→; B: →3)-α-l-Rhap-(1→; C: →2)-α-l-Rhap-(1→; D: →2)-α-l-Rhap(3SO4)-(1→.
1H and 13C chemical shifts for MSP.
| Rhamnose Residues a | Chemical Shifts (ppm) | |||||
|---|---|---|---|---|---|---|
| H1/C1 | H2/C2 | H3/C3 | H4/C4 | H5/C5 | H6/C6 | |
| A | 5.07/103.40 | 4.20/70.79 | 3.93/78.29 | 3.59/73.24 | 3.79/70.79 | 1.35/18.16 |
| B | 5.25/101.86 | 4.30/79.47 | 3.97/70.79 | 3.61/73.24 | 3.80/70.79 | 1.35/18.16 |
| C | 5.35/100.75 | 4.35/79.47 | 4.47/78.29 | 3.61/73.24 | 3.80/70.79 | 1.35/18.16 |
| D | 5.50/100.75 | 4.72/77.00 | 4.10/78.29 | 3.58/73.24 | 3.79/70.79 | 1.35/18.16 |
a A: →3)-α-l-Rhap-(1→; B: →2)-α-l-Rhap-(1→; C: →2)-α-l-Rhap(3SO4)-(1→; D: →3)-α-l-Rhap(2SO4)-(1→. Rhap: rhamnopyranose.
Figure 31H NMR spectra of MSP and MSP-Fs.
Figure 4Anticoagulant activities in vitro by APTT, TT, PT assays on MSP and MSP-Fs. (A) APTT; (B) TT; (C) PT.
Figure 5Anticoagulant and fibrin(ogen)olytic activities in vivo of MSP and MSP-F4. (A) APTT; (B) TT; (C) D-dimer, the D-dimer levels of control, urokinase, MSP at 5 mg/kg and MSP-F4 at 5 mg/kg as well as 10 mg/kg groups were below detection limit in this assay; (D) Plasminogen activator inhibitior-1 (PAI-1), the PAI-1 value of MSP at 10/20 mg/kg and MSP-F4 at 20 mg/kg was up to 0; (E) Fibrin(ogen) degradation products (FDP). Statistical significance: for the anticoagulant activity assay, where ** and ## represented p < 0.01; for the fibrin(ogen)olytic and thrombolytic activity assays, where represented p < 0.05, and represented p < 0.01.
Thrombolytic activities in vitro of MSP and MSP-F4.
| Sample | Concentration | Clot Lytic Rate (%) |
|---|---|---|
| Control | 0 mg/mL | 6.66 ± 0.18 |
| MSP | 5 mg/mL | 13.70 ± 0.62 |
| 10 mg/mL | 20.96 ± 1.91 | |
| 20 mg/mL | 34.29 ± 1.68 | |
| MSP4 | 5 mg/mL | 7.76 ± 0.51 |
| 10 mg/mL | 11.88 ± 1.29 | |
| 20 mg/mL | 20.79 ± 1.17 | |
| Urokinase | 100 U/mL | 22.20 ± 1.39 |
Significance: p < 0.01 vs. the control group; □□ p < 0.01 vs. the urokinase group.